Phase II Study of the Combination of Durvalumab (MEDI4736) (PDL1 Inhibitor) and Olaparib (PARP Inhibitor) in Advanced Cholangiocarcinoma After Initial Chemotherapy and Durvalumab (BIL-PPP)
מצבים רפואיים
Cholangiocarcinoma
סיכום בשפה פשוטהבעזרת בינה מלאכותית
הסיכום נכתב על־ידי מודל שפה והוא ניסיוני. המידע עלול להיות חלקי או שגוי ואינו תחליף לייעוץ רפואי.
מיקומים
Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia
Contact: Principal Investigator (Sara Wahlroos)Monash Medical Centre, Clayton, New South Wales, Australia
Contact: Principal Investigator (Marion Harris)Royal North Shore Hospital, St Leonards, New South Wales, Australia
Westmead Hospital, Westmead, New South Wales, Australia
Contact: Principal Investigator (Adnan Nagrial)Wollongong and Shoalhaven District Memorial Hospital, Wollongong, New South Wales, Australia
Contact: Principal Investigator (Lorraine Chantrill)Princess Alexandra Hospital, Woolloongabba, Queensland, Australia
Contact: Principal Investigator (Laura Tam)Flinders Medical Centre, Bedford Park, South Australia, Australia
Contact: Principal Investigator (Amitesh Roy)Austin Health, Melbourne, Victoria, Australia
Contact: Principal Investigator (Niall Tebbutt)